Tejara Capital Ltd Purchases 24,386 Shares of Establishment Labs Holdings Inc. $ESTA

Tejara Capital Ltd raised its holdings in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 31.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 102,494 shares of the company’s stock after purchasing an additional 24,386 shares during the quarter. Establishment Labs accounts for approximately 2.2% of Tejara Capital Ltd’s portfolio, making the stock its 14th largest position. Tejara Capital Ltd owned about 0.35% of Establishment Labs worth $4,201,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in ESTA. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Establishment Labs by 20.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company’s stock worth $2,335,000 after acquiring an additional 9,557 shares in the last quarter. Patriot Financial Group Insurance Agency LLC boosted its stake in Establishment Labs by 5.2% during the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 6,025 shares of the company’s stock valued at $257,000 after purchasing an additional 300 shares during the last quarter. CWM LLC increased its holdings in Establishment Labs by 45.9% during the 2nd quarter. CWM LLC now owns 2,182 shares of the company’s stock worth $93,000 after purchasing an additional 686 shares in the last quarter. William Blair Investment Management LLC lifted its holdings in shares of Establishment Labs by 2.1% in the second quarter. William Blair Investment Management LLC now owns 865,244 shares of the company’s stock valued at $36,955,000 after purchasing an additional 17,855 shares in the last quarter. Finally, Pier Capital LLC purchased a new position in shares of Establishment Labs during the second quarter valued at approximately $10,777,000. 72.91% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have weighed in on ESTA shares. Citigroup raised their price objective on Establishment Labs from $62.00 to $75.00 and gave the company a “neutral” rating in a research note on Thursday, December 11th. Wall Street Zen raised shares of Establishment Labs from a “sell” rating to a “hold” rating in a research report on Sunday, October 19th. BTIG Research upped their target price on Establishment Labs from $81.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, December 31st. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research report on Monday, December 29th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $84.00 target price on shares of Establishment Labs in a research note on Monday, January 12th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $78.86.

Establishment Labs Stock Performance

NASDAQ ESTA opened at $68.15 on Friday. The firm has a market cap of $1.98 billion, a P/E ratio of -24.00 and a beta of 0.92. The company has a quick ratio of 2.10, a current ratio of 3.33 and a debt-to-equity ratio of 15.06. The company’s 50 day moving average is $70.00 and its 200-day moving average is $53.88. Establishment Labs Holdings Inc. has a 12-month low of $26.56 and a 12-month high of $78.24.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.16. The business had revenue of $53.78 million during the quarter, compared to analyst estimates of $52.28 million. Establishment Labs had a negative net margin of 43.45% and a negative return on equity of 235.45%. Establishment Labs’s revenue was up 33.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.59) EPS. Sell-side analysts predict that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current year.

Establishment Labs Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.